1. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

HeLa cells

" in MCE Product Catalog:

154

Inhibitors & Agonists

1

Dye Reagents

3

Peptides

1

Inhibitory Antibodies

29

Natural
Products

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-144712
    L5-DA

    G-quadruplex Apoptosis Cancer
    L5-DA is a G-quadruplex (G4) ligand and selectively stabilized for G4s over ds26. L5-DA exhibits significant cytotoxicity against HeLa cells (IC50=4.3 μM). L5-DA stabilizes G4s in HeLa cells, induces apoptosis, and cell cycle arrest.
  • HY-103349
    PETCM

    Caspase Apoptosis Cancer
    PETCM is an activator of caspase-3 and acts as an cytochrome c (cyto c)-dependent manner. PETCM promotes Apaf-1 oligomerization and induces cell apoptosis in HeLa cells.
  • HY-110156
    YZ9

    Others Cancer
    Y29 is a potent PFKFB3 inhibitor with an IC50 of 0.183 µM, and acts as a competitive inhibitor against Fru-6-P with a Ki of 0.094 µM. Y29 also inhibits the HeLa cell growth with a GI50 of 2.7 µM.
  • HY-146255
    Apoptosis inducer 10

    Apoptosis Cancer
    Apoptosis inducer 10 is a potent apoptosis inducer. Apoptosis inducer 10 shows antiproliferative effect. Apoptosis inducer 10 induces apoptosis in HeLa cancer cells via a mitochondria-dependent endogenous pathway.
  • HY-146087
    Autophagy inducer 4

    Autophagy Cancer
    Autophagy inducer 4 is a Magnolol-based Mannich base derivatives, which can be used as an anticancer agent. Autophagy inducer 4 suppresses cancer cells via inducing autophagy. Autophagy inducer 4 has 76-fold improvement in cytotoxicity against T47D cells compared with Magnolol. Autophagy inducer 4 also possesses suppressive effects on migration of T47D and Hela cancer cells.
  • HY-118834
    Teleocidin A1

    Lyngbyatoxin A

    PKC Cancer
    Teleocidin A1 (Lyngbyatoxin A), a highly toxic skin irritant, is a potent activator of protein kinase C (PKC). Teleocidin A1 shows antiproliferative activity against HeLa cancer cells (IC50=9.2 nM).
  • HY-N7980
    Rubipodanone A

    NF-κB Cancer
    Rubipodanone A, a naphthohydroquinone dimer, shows cytotoxicity against A549, BEL-7402, HeLa, HepG2, SGC-7901 and U251 cells. Rubipodanone A also shows obvious activating effect at 20 and 40 μM for NF-κB.
  • HY-115947
    Anticancer agent 33

    Others Cancer
    Anticancer agent 33 (compound 3), a Squamocin and Bullatacin derivative, is a potent anticancer agent. Anticancer agent 33 shows high potency to inhibit 4T1 breast cancer cell line (A549, HeLa, HepG2 and MCF-7 cells) growth with IC50s of 1.9-5.4 µM.
  • HY-145291
    CPT-Se4

    Topoisomerase Apoptosis Cancer
    CPT-Se4, a selenoprodrug of Camptothecin (CPT), shows improved potency in killing cancer cells and inhibiting tumor growth. CPT-Se4 decreases the GSH/GSSG ratio and total thiols, elevates the ROS level in Hep G2 cells, and eventually induces apoptosis of cancer cells. CPT-Se4 shows cytotoxicity against HeLa, Hep G2, A549, and SMMC-7721 cells (IC50= 2.54-6.4 μM).
  • HY-145290
    CPT-Se3

    Topoisomerase Apoptosis Cancer
    CPT-Se3, a selenoprodrug of Camptothecin (CPT), shows improved potency in killing cancer cells and inhibiting tumor growth. CPT–Se3 decreases the GSH/GSSG ratio and total thiols, elevates the ROS level in Hep G2 cells, and eventually induces apoptosis of cancer cells. CPT-Se3 shows cytotoxicity against HeLa, Hep G2, A549, and SMMC-7721 cells (IC50= 2.19-4.7 μM).
  • HY-150605
    ERK5-IN-3

    ERK Cancer
    ERK5-IN-3 (compound 33j) is a potent and selective ERK5 (extracellular signal-related kinase 5) inhibitor, with an IC50 of 6 nM. ERK5-IN-3 shows antiproliferation activity against Hela cells, with an IC50 of 31 nM.
  • HY-113505
    Delta-12-Prostaglandin J2

    Δ12-PGJ2

    Endogenous Metabolite Apoptosis Cancer
    Delta-12-Prostaglandin J2 (Δ12-PGJ2) is a cyclopentenone prostaglandin (PG) with anti-proliferative effect on various tumor cell growth. Delta-12-Prostaglandin J2, a naturally occurring dehydration product of prostaglandin D2, is able to induce apoptosis in HeLa cells via caspase activation.
  • HY-145669
    DIF-3

    CDK GSK-3 Cancer
    DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in DLD-1 cells. DIF-3 exerts a strong antiproliferative effect on the human cervical cancer cell line HeLa by inducing cyclin D1 degradation and inhibiting cyclin D1 mRNA expression.
  • HY-144786
    Tubulin polymerization-IN-4

    Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-4 is a potent tubulin polymerization inhibitor with IC50 value of 4.6 μM. Tubulin polymerization-IN-4 can disrupt tubulin polymerization and vasculature, arrest the cell cycle at the G2/M phase, induce apoptosis, and suppress clonogenesis and migration in HeLa cells. Tubulin polymerization-IN-4 can be used for researching cervical cancer.
  • HY-16558
    Butein

    2’,3,4,4’-tetrahydroxy Chalcone

    EGFR Autophagy Apoptosis Phosphodiesterase (PDE) Cancer
    Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4. Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60 c-src in HepG2 cells. Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a. Butein is a SIRT1 activator (STAC).
  • HY-147913
    PI3K/Akt/mTOR-IN-3

    PI3K Akt mTOR Apoptosis Cancer
    PI3K/Akt/mTOR-IN-3 (compound 3d) is a potent PI3K/AKT/mTOR inhibitor. PI3K/Akt/mTOR-IN-3 displays the inhibitory activity in MCF-7, HeLa and HepG2 cells, with IC50 values of 0.77, 1.23, and 4.57μM, respectively. PI3K/Akt/mTOR-IN-3 inhibits the migration of MCF-7 and HeLa cells at the concentration of 4 μM. PI3K/Akt/mTOR-IN-3 induces cell apoptosis and S phase arrest.
  • HY-147852
    B-Raf IN 7

    Raf Cancer
    B-Raf IN 7 (compound 6a) is a potent B-Raf inhibitor, with an IC50 of 110.23 nM. B-Raf IN 7 exhibits antitumor activity against colon carcinoma (HCT-116), mammary gland (MCF-7), hepatocellular carcinoma (HEPG-2), human cervical carcinoma (Hela) and human prostate cancer (PC-3) cells, with IC50 values of 7.50, 9.87, 10.57, 11.63 and 12.83 µM.
  • HY-147690
    Photosensitizer-2

    Others Cancer
    Photosensitizer-2 (compound 1) is a organic D-π-A sensitizer against phototoxicity. Photosensitizer-2 contains an acrylic acid moiety that exerts high levels of phototoxicity. Photosensitizer-2 shows antitumor activity against HeLa cells, with IC50 values of 20.9 ± 4.5 μM (dark) and 0.046 ± 0.012 μM (irradiation), respectively.
  • HY-N8015
    Octanal

    Bacterial Endogenous Metabolite Cancer Infection
    Octanal is an aromatic aldehyde, with antioxidant and antimicrobial activities. Octanal shows cytotoxicity against Hela cells.
  • HY-12053A
    Vinorelbine ditartrate

    KW-2307; Nor-5'-anhydrovinblastine ditartrate

    Microtubule/Tubulin Autophagy Cancer
    Vinorelbine (ditartrate) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.
  • HY-N10542
    Aplyronine C

    Others Cancer
    Aplyronine C is an active compound. Aplyronine C shows potent antitumor activity and has cytotoxicity against HeLa-S3 cells with an IC50 values of 22 nM. Aplyronine C can be used for the research of cancer.
  • HY-N10541
    Aplyronine B

    Others Cancer
    Aplyronine B is an active compound. Aplyronine B shows potent antitumor activity and has cytotoxicity against HeLa-S3 cells with an IC50 values of 2.9 nM. Aplyronine B can be used for the research of cancer.
  • HY-10225
    Belinostat

    PXD101; PX105684

    HDAC Autophagy Cancer
    Belinostat (PXD101; PX105684) is a potent HDAC inhibitor with an IC50 of 27 nM in HeLa cell extracts.
  • HY-112716
    N-alpha-Tosyl-L-lysine chloromethyl ketone hydrochloride

    Others Cancer
    N-alpha-Tosyl-L-lysine chloromethyl ketone (TLCK), a trypsin like protease inhibitor, sensitizes HeLa cells to Fas-mediated cell death.
  • HY-144468
    IDO1-IN-17

    Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1-IN-17 (I-4) is an IDO1 inhibitor, with an IC50 of 0.44 μM in hela cells.
  • HY-A0068
    Aurothioglucose

    Gold thioglucose

    Others Cancer
    Aurothioglucose (Gold thioglucose) is a well known active-site inhibitor of TrxR1, inhibited TrxR1 activity in HeLa cell cytosol but had no effect on the viability of the cells.
  • HY-N10394
    Metachromins X

    Others Cancer
    Metachromins X is a sesquiterpene quinone that arrests the cell cycle progression of HeLa/Fucci2 cells at S/G2/M phase.
  • HY-150411
    Cys-C-cGMP

    AUTACs Cancer
    Cys-C-cGMP is a autophagy tag for AUTACs. Cys-C-cGMP can increase the K63-linked ubiquitination of mitochondria in HeLa cells.
  • HY-N4208
    Taccalonolide AJ

    Microtubule/Tubulin Cancer
    Taccalonolide AJ is a semi-synthesis compound with cellular microtubule stabilizing activity. Taccalonolide AJ exhibits high potency antiproliferative activity against cancer cells, with an IC50 of 4.2 nM for HeLa cells.
  • HY-N3558
    Ceanothic acid

    Emmolic acid

    Others Cancer
    Ceanothic acid (Emmolic acid) is a ring-A homologue of betulinic acid. Ceanothic acid inhibits OVCAR-3, HeLa, and FS-5 cells with the cell survival of 68%, 65%, and 81%, respectively.
  • HY-146261
    HI5

    Microtubule/Tubulin Indoleamine 2,3-Dioxygenase (IDO) Apoptosis Cancer
    HI5 is a potent tublin and IDO inhibitor, with an IC50 value of 70 nM in HeLa cells. HI5 inhibit IDO expression and decrease kynurenine production, leading to stimulating T cells activation and proliferation. HI5 can inhibit tubulin polymerization and cell migration, cause G2/M phase arrest, and induce apoptosis via the mitochondrial dependent apoptosis pathway and cause reactive oxidative stress generation in HeLa cells. HI5 can be used for researching anticancer.
  • HY-100541
    INH6

    Apoptosis Cancer
    INH6 is a potent Nek2/Hec1 inhibitor; inhibits the growth of HeLa cells with an IC50 of 2.4 μM.
  • HY-150409
    TSPO ligand-2

    AUTACs Cancer
    TSPO ligand-2 is a ligand of AUTAC1. AUTAC1 contains an p-fluorobenzylguanine (FBnG) and a Fumagillol moiety, which can silence endogenous MetAP2 in HeLa cells.
  • HY-N2213
    Matairesinol 4′-O-β-D-glucopyranoside

    Others Cancer
    Matairesinol 4′-O-β-D-glucopyranoside displays cytotoxic activity against HeLa cell line with an IC50 of 47.1 μM.
  • HY-120337
    V-11-0711

    Others Cancer
    V-11-0711 is a potent and selective choline kinase alpha (ChoKα) inhibitor with an IC50 of 20 nM. V-11-0711 causes a reversible growth arrest in HeLa cells.
  • HY-B2054
    Tebufenozide

    Apoptosis Others
    Tebufenozide is a nonsteroidal ecdysone agonist used to control pest. Tebufenozide has cytotoxic and induces apoptosis in HeLa and insect Tn5B1-4 cells.
  • HY-150655
    Hsp90-IN-15

    HSP Cancer
    Hsp90-IN-15 is an Hsp90 inhibitor with anticancer activity. Hsp90-IN-15 induces cell apoptosis, arrests the cell cycle at S phase and decreases the expression level of Hsp90 in Hela cell.
  • HY-13057
    O6BTG-octylglucoside

    Glucose-conjugated MGMT inhibitor

    DNA Methyltransferase Cancer
    O6BTG-octylglucoside is a potent O 6-methylguanine-DNAmethyl-transferase (MGMT) inhibitor, with IC50s of 32 nM in vitro (cell extracts) and 10 nM in HeLa S3 cells.
  • HY-141861
    Anticancer agent 17

    Others Cancer
    Anticancer agent 17 displays potent anticancer activities against HeLa and A2780 cells with IC50 values of 0.19 μM and 0.09 μM, respectively.
  • HY-117154
    INH154

    Others Cancer
    INH154 is a highly potent inhibitor for Nek2 and Hec1 binding (INH), with IC50s of 200 nM and 120 nM for INH in Hela and MB468 cells.
  • HY-128599
    NMS-P515

    PARP Cancer
    NMS-P515 is a potent, orally active and stereospecific PARP-1 inhibitor, with a Kd of 16 nM and an IC50 of 27 nM (in Hela cells). Anti-tumor activity.
  • HY-106161
    Rupintrivir

    AG7088

    Virus Protease Enterovirus Infection Inflammation/Immunology
    Rupintrivirvr (AG7088), an antiviral drug, is a potent, selective and irreversible inhibitor of human rhinovirus (HRV) 3C protease. Rupintrivirvr inhibits replication of a panel of 48 different HRV serotypes in H1-HeLA and MRC-5 cell protection assays, with a mean EC50 of 0.023 μM. Rupintrivirvr shows immune-modulatory effect.
  • HY-150410
    TSPO ligand-3

    AUTACs Cancer
    TSPO ligand-3 is a ligand of AUTAC2. AUTAC2 contains an p-fluorobenzylguanine (FBnG) and an synthetic ligand of FKBP (SLF) moiety, which can cause significant silencing of FKBP12 in HeLa cells.
  • HY-N0144
    Piperine

    Bioperine; 1-Piperoylpiperidine

    P-glycoprotein Autophagy Endogenous Metabolite Inflammation/Immunology Cancer
    Piperine, a natural alkaloid isolated from Piper nigrum L, inhibits P-glycoprotein and CYP3A4 activities with an IC50 value of 61.94±0.054 μg/mL in HeLa cell.
  • HY-126989
    19-O-Acetylchaetoglobosin A

    Others Cancer
    19-O-Acetylchaetoglobosin A, a cytochalasan alkaloid, is a fungal metabolite originally isolated from C. globosum that has actin polymerization inhibitory and cytotoxic activities. 19-O-Acetylchaetoglobosin A is cytotoxic to HeLa cervical cancer cells.
  • HY-12033
    2-Methoxyestradiol

    2-ME2; NSC-659853

    Microtubule/Tubulin Reactive Oxygen Species Apoptosis Autophagy Endogenous Metabolite Cancer
    2-Methoxyestradiol (2-ME2), an orally active endogenous metabolite of 17β-estradiol (E2), is an apoptosis inducer and an angiogenesis inhibitor with potent antineoplastic activity. 2-Methoxyestradiol also destablize microtubules. 2-Methoxyestradio, also a potent superoxide dismutase (SOD) inhibitor and a ROS-generating agent, induces autophagy in the transformed cell line HEK293 and the cancer cell lines U87 and HeLa.
  • HY-N9532
    Isobyakangelicol

    Anhydrobyakangelicin

    Others Cancer
    Isobyakangelicol is a coumarin that can be found in the roots of Angelica dahurica. Isobyakangelicol inhibits the growth of HeLa and HepG2 cells, with IC50s of 70.04 μM and 17.97 μM.
  • HY-N7654
    (-)-Epipodophyllotoxin

    Apoptosis Cancer
    (-)-Epipodophyllotoxin (2) is an antiproliferative agent against cancer cells isolated from American mayapple Podophyllum peltatum, with GI50s of 0.36 and 0.24 μM in HeLa cells and MCF-7 cells, respectively. (-)-Epipodophyllotoxin can inhibit mitotic spindle assembly in vitro.
  • HY-137498
    EBOV/MARV-IN-1

    Filovirus Infection
    EBOV/MARV-IN-1 is a potent inhibitor of Ebola virus (EBOV) and Marburg virus (MARV), with broad-spectrum activity (EC50=0.31, and 0.82 µM, respectively) and low cytotoxicity (SI>100) in HeLa cells.
  • HY-122751
    (R)-DNMDP

    Phosphodiesterase (PDE) Cancer
    (R)-DNMDP is a potent and selective cancer cell cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, binds PDE3A directly. (R)-DNMDP has a 500-fold lower EC50 compared to the (S)-enantiomer in HeLa cell line.
  • HY-12053AS
    Vinorelbine-d3 ditartrate

    KW-2307-d3 ditartrate; Nor-5'-anhydrovinblastine-d3 ditartrate

    Microtubule/Tubulin Autophagy Cancer
    Vinorelbine-d3 (KW-2307-d3) ditartrate is the deuterium labeled Vinorelbine ditartrate. Vinorelbine (ditartrate) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.
  • HY-B0497
    Niclosamide

    BAY2353

    STAT Parasite Antibiotic Infection Cancer
    Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells.
  • HY-B0497A
    Niclosamide sodium

    BAY2353 sodium

    Antibiotic STAT Parasite Cancer Infection
    Niclosamide (BAY2353) sodium is an orally active antihelminthic agent used in parasitic infection research. Niclosamide sodium is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells. Niclosamide sodium has biological activities against cancer, and inhibits DNA replication in Vero E6 cells.
  • HY-B0497B
    Niclosamide monohydrate

    BAY2353 monohydrate

    STAT Antibiotic Parasite Cancer Infection
    Niclosamide (BAY2353) monohydrate is an orally active antihelminthic agent used in parasitic infection research. Niclosamide monohydrate is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells. Niclosamide monohydrate has biological activities against cancer, and inhibits DNA replication in Vero E6 cells.
  • HY-N10332
    Leptosphaerodione

    Proteasome Cancer
    Leptosphaerodione, isolated from Remotididymella sp. Fungus, is a potent ubiquitin-proteasome system (UPS) inhibitor. Leptosphaerodione exhibits cytotoxicity in HeLa cells with IC50 value of 3.2 μM. Anti-tumor agent.
  • HY-100771
    PCC0208009

    Indoleamine 2,3-Dioxygenase (IDO) Cardiovascular Disease
    PCC0208009 is a potent IDO inhibitor with an IC50 value of 4.52 nM in HeLa cell. PCC0208009 alleviates neuropathic pain and comorbidities by regulating synaptic plasticity of anterior cingulate cortex (ACC) and amygdala .
  • HY-77572
    7-Epi 10-desacetyl paclitaxel

    7-epi-10-deacetyltaxol; 10-Deacetyl-7-epipaclitaxel

    Others Cancer
    7-Epi 10-desacetyl paclitaxel (7-epi-10-deacetyltaxol), a taxol derivative, exhibits cytotoxicity against HeLa cells with an IC50 of 85 μM.
  • HY-N10351
    27-O-(tert-Butyldimethylsilyl)withaferin A

    Apoptosis Cancer
    27-O-(tert-Butyldimethylsilyl)withaferin A (compound 9a), a natural withanolide, is an apoptosis inducer. 27-O-(tert-Butyldimethylsilyl)withaferin A shows antiproliferative activity against HeLa, A-549 and MCF-7 human cancer cell lines, and against normal Vero cells.
  • HY-146411
    microRNA-21-IN-1

    MicroRNA Apoptosis Cancer
    microRNA-21-IN-1 (compound 7A) is an efficient microRNA inhibitor. microRNA-21-IN-1 has antiproliferative activity against Hela and HCT-116 cells with IC50s of 5.5 μM and 2.8 μM respectively, as well as promotes apoptosis of Hela cells. microRNA-21-IN-1 upregulates the expression of microRNA-21 downstream functional targets (PTEN, EGR1 and SLIT2). microRNA-21-IN-1 can be used for researching anticancer.
  • HY-100853
    IWP-O1

    Porcupine Wnt Cancer
    IWP-O1 is a highly potent Porcupine (Porcn) inhibitor, with an EC50 of 80 pM in L-Wnt-STF cells. IWP-O1 prevents the secretion of Wnt proteins. IWP-O1 suppresses the phosphorylation of Dvl2/3 and LRP6 in HeLa cells.
  • HY-146082
    (Z)-α-Cyanostilbene

    Others Cancer
    (Z)-α-Cyanostilbene (compound 8), a dicyano substituted acrylonitrile, shows selective antiproliferative activity against HeLa and HepG2 cells, with IC50s of 0.33 and 0.52 μM, respectively.
  • HY-B0497C
    Niclosamide olamine

    BAY2353 olamine

    STAT Parasite Antibiotic Cancer Infection
    Niclosamide (BAY2353) olamine is an orally active antihelminthic agent used in parasitic infection research. Niclosamide olamin is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells. Niclosamide olamin has biological activities against cancer, and inhibits DNA replication in Vero E6 cells.
  • HY-122571
    Retro-2

    Filovirus Parasite Autophagy Cancer Infection
    Retro-2 is a selective inhibitor of retrograde protein trafficking at the endosome-trans-Golgi network interface. Retro-2 is an ebolavirus (EBOV) infection inhibitor with an EC50 of 12.2 µM in HeLa cells. Retro-2 induces cell autophagy.
  • HY-N7507
    Sempervirine

    Others Cancer
    Sempervirine is an indole alkaloid isolated from Gelsemium sempervirens with anti-tumor activities. Sempervirine is against sempervirine-sensitive tumor cells with EC50 values of 2.7 μM, 1.77 μM, and 1.96 μM for Raji, MDA-MB-231 and HeLa cells, respectively.
  • HY-12033S2
    2-Methoxyestradiol-d5

    2-ME2-d5; NSC-659853-d5

    Microtubule/Tubulin Reactive Oxygen Species Apoptosis Autophagy Endogenous Metabolite
    2-Methoxyestradiol-d5 is the deuterium labeled 2-Hydroxyestradiol. 2-Methoxyestradiol (2-ME2), an orally active endogenous metabolite of 17β-estradiol (E2), is an apoptosis inducer and an angiogenesis inhibitor with potent antineoplastic activity. 2-Methoxyestradiol also destablize microtubules. 2-Methoxyestradio, also a potent superoxide dismutase (SOD) inhibitor and a ROS-generating agent, induces autophagy in the transformed cell line HEK293 and the cancer cell lines U87 and HeLa.
  • HY-106161S
    Rupintrivir-d4

    AG7088-d4

    Virus Protease Enterovirus Infection Inflammation/Immunology
    Rupintrivir-d4 (AG7088-d4) is the deuterium labeled Rupintrivir. Rupintrivirvr (AG7088), an antiviral drug, is a potent, selective and irreversible inhibitor of human rhinovirus (HRV) 3C protease. Rupintrivirvr inhibits replication of a panel of 48 different HRV serotypes in H1-HeLA and MRC-5 cell protection assays, with a mean EC50 of 0.023 μM. Rupintrivirvr shows immune-modulatory effect.
  • HY-N8512
    Asperfuran

    Fungal Infection
    Asperfuran is an antifungal dihydrobenzofuran derivative produced by a strain of Aspergillus oryzae. Asperfuran weakly inhibits chitin synthase from Coprinus cinereus. Asperfuran shows weak cytotoxicity In HeLa S3 and L1210 cells with an IC50 of 25 μg/ml.
  • HY-146692
    IQTub4P

    Microtubule/Tubulin Cancer
    IQTub4P is a potent microtubule (MT) inhibitor. IQTub4P has the cytotoxicity in in HeLa cells, with EC50 of 170 nM. IQTub4P inhibits microtubule structure and function. IQTub4P is well-tolerated in vivo.
  • HY-110387
    IDO-IN-9

    Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO-IN-9 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50s of 0.011 μM (Kinase) and 0.0018 μM (Hela Cell), extracted from patent WO 2016041489 A1, compound 6.
  • HY-111234
    IDO-IN-11

    Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO-IN-11 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50s of 0.18 μM (Kinase) and 0.014 μM (Hela Cell), extracted from patent WO 2016041489 A1, compound 13.
  • HY-N1833
    3'-Geranyl-3-prenyl-2',4',5,7-tetrahydroxyflavone

    Others Cancer
    3'-Geranyl-3-prenyl-2',4',5,7-tetrahydroxyflavone displays cytotoxicity of 1.32, 3.92 and 5.22 μm against the human cervical carcinoma HeLa, human breast carcinoma MCF-7, and human hepatocarcinoma Hep3B cells.
  • HY-B0497S1
    Niclosamide-13C6

    BAY2353-13C6

    STAT Parasite Antibiotic Infection Cancer
    Niclosamide-13C6 is the 13C6 labeled Niclosamide. Niclosamide (BAY2353) is an orally bioavailable chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity. Niclosamide (BAY2353) inhibits STAT3 with IC50 of 0.25 μM in HeLa cells and inhibits DNA replication in a cell-free assay.
  • HY-12033S
    2-Methoxyestradiol-13C,d3

    Microtubule/Tubulin Reactive Oxygen Species Apoptosis Autophagy Endogenous Metabolite Cancer
    2-Methoxyestradiol-13C,d3 is the 13C- and deuterium labeled 2-Methoxyestradiol. 2-Methoxyestradiol (2-ME2), an orally active endogenous metabolite of 17β-estradiol (E2), is an apoptosis inducer and an angiogenesis inhibitor with potent antineoplastic activity. 2-Methoxyestradiol also destablize microtubules. 2-Methoxyestradio, also a potent superoxide dismutase (SOD) inhibitor and a ROS-generating agent, induces autophagy in the transformed cell line HEK293 and the cancer cell lines U87 and HeLa.
  • HY-N10353
    4-Methyl withaferin A

    Others Cancer Inflammation/Immunology
    4-Methyl withaferin A is a withaferin A-analogue with anti-tumor activity.
  • HY-N7623
    Ursonic acid methyl ester

    Others Cancer
    Ursonic acid methyl ester is an esterified derivative of Ursolic acid (HY-N0140). Ursonic acid methyl ester shows growth inhibitory activity against four tumor cell lines, HL-60, BGC, Bel-7402 and Hela with ED50 values of >100 µg/ml.
  • HY-114372
    Lycopodine

    Lipoxygenase Caspase Apoptosis Cancer
    Lycopodine, a pharmacologically important bioactive component derived from Lycopodium clavatumspores, triggers apoptosis by modulating 5-lipoxygenase, and depolarizing mitochondrial membrane potential in refractory prostate cancer cells without modulating p53 activity. Lycopodine inhibits proliferation of HeLa cells through induction of apoptosis via caspase-3 activation.
  • HY-100591
    SirReal2

    Sirtuin Cancer Inflammation/Immunology Neurological Disease
    SirReal2 is a potent, isotype-selective Sirt2 inhibitor with an IC50 value of 140 nM and has very little effect on the activities of Sirt3-5. SirReal2 leads to tubulin hyperacetylation in HeLa cells and induces destabilization of the checkpoint protein BubR1.
  • HY-147896
    Tubulin polymerization-IN-29

    Microtubule/Tubulin Cancer
    Tubulin polymerization-IN-29 (compound 6g) is a potent tubulin polymerization inhibitor. Tubulin polymerization-IN-29 exhibits potent antiproliferative activity. Tubulin polymerization-IN-29 can induce HeLa cells arrest in G2/M phase.
  • HY-16658B
    Z-VAD-FMK

    Z-VAD(OH)-FMK

    Caspase Cancer
    Z-VAD-FMK (Z-VAD(OH)-FMK) is a well-know pan caspase inhibitor, which does not inhibit ubiquitin carboxy-terminal hydrolase L1 (UCHL1) activity even at concentrations as high as 440 μM.
  • HY-13961
    GLPG0634 analog

    JAK Cancer
    GLPG0634 analog (Compoun 176) is a broad spectrum JAK inhibitor with IC50 values of <100 nM against JAK1, JAK2 and JAK3.
  • HY-19805
    STO-609

    CaMK AMPK Autophagy Metabolic Disease
    STO-609 is a selective and cell-permeable inhibitor of the Ca 2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC50 ~0.02 g/ml.
  • HY-108262
    UCN-02

    7-epi-Hydroxystaurosporine

    PKC PKA Cancer
    UCN-02 (7-epi-Hydroxystaurosporine) is a selective protein kinase C (PKC) inhibitor produced by Streptomyces strain N-12, with IC50s of 62 nM and 250 nM for PKC and protein kinase A (PKA), respectively. UCN-02 (7-epi-Hydroxystaurosporine) displays cytotoxic effect on the growth of HeLa S3 cells.
  • HY-12033S1
    2-Methoxyestradiol-13C6

    2-ME2-13C6; NSC-659853-13C6

    Microtubule/Tubulin Reactive Oxygen Species Apoptosis Autophagy Endogenous Metabolite Cancer
    2-Methoxyestradiol-13C6 (2-ME2-13C6) is the 13C-labeled 2-Methoxyestradiol. 2-Methoxyestradiol (2-ME2), an orally active endogenous metabolite of 17β-estradiol (E2), is an apoptosis inducer and an angiogenesis inhibitor with potent antineoplastic activity. 2-Methoxyestradiol also destablize microtubules. 2-Methoxyestradio, also a potent superoxide dismutase (SOD) inhibitor and a ROS-generating agent, induces autophagy in the transformed cell line HEK293 and the cancer cell lines U87 and HeLa.
  • HY-119401
    CAY10444

    BML-241

    LPL Receptor Cancer
    CAY10444 (BML-241) is a sphingosine-1-phosphate 3 (S1P3) antagonist. CAY10444 inhibits by 37% S1P-induced increases in Ca2+ in HeLa cells expressing S1P3 receptors.
  • HY-N1511
    Ganoderic acid D

    Sirtuin Apoptosis Cancer
    Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of SIRT3 and induces the deacetylated cyclophilin D (CypD) by SIRT3. Ganoderic acid D inhibits the energy reprogramming of colon cancer cells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in colon cancer cells. Ganoderic acid D induces HeLa human cervical carcinoma apoptosis.
  • HY-144396
    SHP2-IN-8

    Phosphatase Akt Apoptosis Cancer
    SHP2-IN-8 is a highly potent, selective, and cellularly active allosteric SHP2 inhibitor with IC50 value of 23 nM and Ki of 22 nM. SHP2-IN-8 is reversible and noncompetitive. SHP2-IN-8 causes a significant thermal shift with the ΔTm of 7.01 ℃. SHP2-IN-8 induces the apoptosis and inhibits the phosphorylation of AKT in Hela cells.
  • HY-101775A
    9-Hydroxyellipticine hydrochloride

    Topoisomerase Cancer Cardiovascular Disease
    9-Hydroxyellipticine hydrochloride is a inhibitor of Topo II and RyR. 9-Hydroxyellipticine hydrochloride exhibits antitumor, antioxidant and catecholamine-releasing activities. 9-Hydroxyellipticine hydrochloride exhibits IC50 values of 1.6 μM and 1.2μM in Hela S-3 and 293T cells, respectively.
  • HY-150408
    FBnG-(Cys-acetamide)-CH2-PEG3-CH2-CH2-CH2-NH2

    AUTACs Cancer
    FBnG-(Cys-acetamide)-CH2-PEG3-CH2-CH2-CH2-NH2 is a linker of AUTAC4. AUTAC4 contains an p-fluorobenzylguanine (FBnG) and a phenylindole moiety, which can induce K63-linked polyubiquitination and degradation of mitochondria in HeLa cells.
  • HY-139290
    RGLS4326

    RG4326

    Others Cancer Metabolic Disease
    RGLS4326 (RG4326) is a first-in-class, short oligonucleotide inhibitor of microRNA-17 (miR-17). RGLS4326 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 inhibits miR-17 function in HeLa cells with an EC50 value of 28.3 nM.
  • HY-N10354
    27-Methyl withaferin A

    Apoptosis Cancer
    27-Methyl withaferin A (comppund 26) is an apoptosis inducer with anticancer effects. 27-Methyl withaferin A shows antiproliferative effects against HeLa, A-549 and MCF-7 human tumor cell lines with IC50 values of 3.2 μM, 4.2 μM and 1.4 μM, respectively.
  • HY-108992
    Deoxynyboquinone

    Apoptosis Reactive Oxygen Species Cancer
    Deoxynyboquinone, an excellent NQO1 substrate, is a potent antineoplastic agent. Deoxynyboquinone induces apoptosis in cancer cell lines. Deoxynyboquinone kills cancer cells through oxidative stress and reactive oxygen species (ROS) formation.
  • HY-118630
    Vacuolin-1

    PIKfyve Autophagy Cancer
    Vacuolin-1 is a potent and cell-permeable lysosomal exocytosis inhibitor. Vacuolin-1 blocks the Ca 2+-dependent exocytosis of lysosomes and prevents the release of lysosomal content without affecting the process of resealing. vacuolin‐1 is a potent and selective PIKfyve inhibitor and inhibits late‐stage autophagy by impairing lysosomal maturation.
  • HY-146169
    Antitumor agent-68

    Reactive Oxygen Species Microtubule/Tubulin Cancer
    Antitumor agent-68 is a potent tubulin inhibitor. Antitumor agent-68 shows potent anticancer activity with IC50s of 3.6 and 3.8 µM for HeLa and MCF-7 cells, respectively. Antitumor agent-68 exhibits good scavenging activity of ROS and DPPH radical in a dose-dependent manner.
  • HY-150511
    3-(3-Phenoxybenzyl)amino-β-carboline

    Microtubule/Tubulin Apoptosis Cancer
    3-(3-Phenoxybenzyl)amino-β-carboline is a potent tubulin inhibitor. 3-(3-Phenoxybenzyl)amino-β-carboline promotes selective degradation of αβ-tubulin heterodimers. 3-(3-Phenoxybenzyl)amino-β-carboline induces G2/M phase cell cycle arrest and apoptosis. 3-(3-Phenoxybenzyl)amino-β-carboline exhibits anticancer activity.
  • HY-126318
    Demethoxydeacetoxypseudolaric acid B analog

    Others Cancer
    Demethoxydeacetoxypseudolaric acid B analog (Compound 13b) is semi-synthesized by efficient routines from Pseudolaric acid B. It has potent activities against HMEC-1, HL-60, A-549, MB-MDA-468, BEL-7402, HCT116, and Hela cells with IC50s ranging from 0.136 to 1.162 μM.
  • HY-135691
    hnRNPK-IN-1

    c-Myc Apoptosis Cancer
    hnRNPK-IN-1 is a heterogeneous nuclear ribonucleoprotein K (hnRNPK) binding ligand with Kd values of 4.6 μM and 2.6 μM measured with SPR and MST, respectively. hnRNPK-IN-1 inhibits c-myc transcription by disrupting the binding of hnRNPK and c-myc promoter. hnRNPK-IN-1 induces Hela cells apoptosis and has strongly anti-tumor activities.
  • HY-145865
    c-Met/MEK1/Flt-3-IN-1

    Apoptosis Cancer
    Antiproliferative against-3 (comp 33) shows a prominent activity against Hela (IC50 = 0.21 µM), A549 (IC50 = 0.39 µM), and MCF-7 (IC50 = 0.33 µM), respectively. Antiproliferative against-3 (comp 33) also dose dependently induces apoptosis by arresting A549 cells at G1 phase.
  • HY-143301
    Topoisomerase I inhibitor 4

    Topoisomerase Cancer
    Topoisomerase I inhibitor 4 (compound 7a) is a topoisomerase I inhibitor. Topoisomerase I inhibitor 4 inhibits HepG2, A549, MCF-7 and HeLa cancer cells proliferation with IC50s of 1.20, 2.09, 1.56 and 1.92 μM, respectively. Topoisomerase I inhibitor 4 can be used for the research of cancer.
  • HY-146221
    Dyrk1A-IN-5

    DYRK Neurological Disease
    Dyrk1A-IN-5 (compound 5j) is a potent and selective DYRK1A inhibitor, with an IC50 of 6 nM. Dyrk1A-IN-5 dose-dependently reduces the phosphorylation of Thr434 in SF3B1, with an IC50 of 0.5 μM. Dyrk1A-IN-5 inhibits phosphorylation of tau at Thr212, with an IC50 of 2.1 μM. Dyrk1A-IN-5 can be used for Down syndrome research.
  • HY-144273
    IDO1-IN-13

    Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1-IN-13 (compound 27a) is a potent IDO1 inhibitor with an IC50 of 61.6 nM. IDO1-IN-13 has cellular IDO1 inhibition (HeLa EC50= 30 nM). IDO1-IN-13 decreases 51% of the kyn/trp ratio in SK-OV-3 xenograft tumor tissues.
  • HY-144274
    IDO1-IN-14

    Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1-IN-14 (compound 4a) is a potent IDO1 inhibitor with an IC50 of 396.9 nM. IDO1-IN-14 has cellular IDO1 inhibition (HeLa EC50=3393 nM).
  • HY-146144
    HIF-IN-1

    HIF/HIF Prolyl-Hydroxylase Cancer
    HIF-IN-1 (Compound 3c) is a hypoxia-inducible factor (HIF)-1 inhibitor. HIF-IN-1 suppresses HIF-1α protein accumulation without affecting the levels of HIF-1α mRNA. HIF-IN-1 shows no obvious cytotoxicity.
  • HY-147977
    ALR1/2-IN-1

    Aldose Reductase Cancer
    ALR1/2-IN-1 (Compound 6e) is an aldehyde reductase (ALR1) and aldose reductase (ALR2) inhibitor with IC50 values of 3.26 μM and 3.06 μM against ALR1 and ALR2, respectively. ALR1/2-IN-1 shows anticancer activity.
  • HY-150614
    Autotaxin-IN-6

    Phosphodiesterase (PDE) LPL Receptor Cancer
    Autotaxin-IN-6 (compound 23) is a potent autotaxin (ATX) inhibitor with an IC50 value of 30 nM. Autotaxin-IN-6 can reduce cell migration. Autotaxin-IN-6 can be used for researching anticancer.
  • HY-146083
    (Z)-p-cyano-α-Cyanostilbene

    Others Cancer
    (Z)-p-cyano-α-Cyanostilbene (compound 11), a phenantrene derivative, has antiproliferative activity. (Z)-p-cyano-α-Cyanostilbene shows significant selectivity against HeLa (IC50=0.21 µM) and HepG2 (IC50=0.230 µM) cells without cytotoxic against normal skin fibroblasts (IC50>100 µM).
  • HY-147947
    Tubulin polymerization-IN-30

    Microtubule/Tubulin Cancer
    Tubulin polymerization-IN-30 (compound 6e) is a potent Tubulin polymerization inhibitor. Tubulin polymerization-IN-30 is a colchicine binding site inhibitor. Tubulin polymerization-IN-30 can disrupt intracellular microtubule organization, arrest cell cycle at the G2/M phase. Tubulin polymerization-IN-30 exhibits the high potency against the cancer cell lines including SGC-7901, A549 and HeLa, with IC50 values of 2.16, 2.21, and 0.403 μM.
  • HY-151486
    GLUT1-IN-1

    Others Cancer
    GLUT1-IN-1 is a chromophore-assisted light inactivation (CALI) photosensitizer. GLUT1-IN-1 exhibits concentration-dependent cytotoxicity for HeLa, A549 and HepG2 cells with IC50 values of 5.49 μM, 11.14 μM, and 8.73 μM, respectively. GLUT1-IN-1 can be used for the research of photodynamic therapy (PDT) and severals cancer.
  • HY-151474
    SARS-CoV-2-IN-31

    SARS-CoV Cancer
    SARS-CoV-2-IN-31 is an effective COVID-19 inhibitor. SARS-CoV-2-IN-31 exhibits excellent to mild activity against various cancer cell lines with IC50 values range from 28.84 to 38.36 μM. SARS-CoV-2-IN-31 can be used for the research of cancer.
  • HY-147504
    Anticancer agent 63

    Apoptosis Caspase Bcl-2 Family Cancer
    Anticancer agent 63 (compound 3h) shows active in reducing the viability of different cancer cell lines, including SW480, HeLa, A549 and MCF-7, with IC50 values at 24 h of 4.9, 11.5, 9.4, and 3.4 μM, respectively. Anticancer agent 63 induce apoptosis in MCF-7 cells via down-regulating the expression of Bcl-2 and up-regulating the expression of IL-2 and Caspase-3. Anticancer agent 63 also shows antioxidant activity.
  • HY-138820
    SW02

    Neurological Disease
    SW02 is a potent activator of ATPase activity of Hsp70, with an EC50 of 150 μM. SW02 leads to accumulation of both total tau and phosphorylated tau (pTau).
  • HY-N3119
    Paeoniflorigenone

    Apoptosis Cancer
    Paeoniflorigenone, isolated as an active ingredient from the root of moutan cortex, induces apoptosis selectively in the cancer cell lines and exhibits antiproliferative effect.
  • HY-18700
    BRD73954

    HDAC Cancer
    BRD73954 is a potent HDAC inhibitor and selectively inhibiting both HDAC6 and HDAC8 with IC50 values of 0.0036, 0.12, 9, 12, 23 µM for HDAC6, HDAC8, HDAC2, HDAC1 and HDAC3, respectively. BRD73954 decreases the levels of HDAC6, associated with upregulation of Ac-Tubulin.
  • HY-15672
    FM19G11

    HIF/HIF Prolyl-Hydroxylase Cancer Neurological Disease
    FM19G11 is a hypoxia-inducible factor-1-alpha (HIF-1α) inhibitor, and it inhibits hypoxia-induced luciferase activity with an IC50 of 80 nM in HeLa cells. FM19G11 modulates other signaling pathways, including mTOR and PI3K/Akt/eNOS, when the HIF-1α pathway is inactivated under normoxic conditions.
  • HY-143233
    PIM-1/HDAC-IN-1

    Pim HDAC Apoptosis Cancer
    PIM-1/HDAC-IN-1 (compound 4d) is a PIM-1 inhibitor, with an IC50 of 343.87 nM. PIM-1/HDAC-IN-1 has strong inhibitory activity and selectivity against HDAC 1 and HDAC 6, with IC50 values of 63.65 and 62.39 nM, respectively. PIM-1/HDAC-IN-1 exhibits apoptosis inducing potential in MCF-7 cell lines. PIM-1/HDAC-IN-1 shows pre-G1 apoptosis and cell cycle arrest at G2/M phase.
  • HY-N1039A
    Manool

    Others Cancer
    Manool is a diterpene from Salvia officinalis. Manool induces selective cytotoxicity in cancer cells. Manool arrests the cancer cells at the G(2)/M phase of the cell cycle.
  • HY-N3985
    Gyrophoric acid

    Others Cancer
    Gyrophoric acid is a good ultraviolet filter in lichen populations. Gyrophoric acid shows DPPH radical scavenging activity with an IC50 value of 105.75 µg/ml.
  • HY-131058
    Muscotoxin A

    ADC Cytotoxin Cancer
    Muscotoxin A is an ADC cytotoxin. Muscotoxin A is a cytotoxic lipopeptide that permeabilizes mammalian cell membranes and induces necrotic cell death.
  • HY-137975
    Exo2

    Others Endocrinology
    Exo2 is a secretion inhibitor. Exo2 perturbs trafficking of Shiga toxin between endosomes and the trans-Golgi network. Exo2 blocks secretory cargo exit from the ER (endoplasmic reticulum) and disrupts the Golgi apparatus, but does not affect the morphology of the TGN (trans-Golgi network) Exo2 can stimulate calcium-dependent exocytosis in permeabilized adrenal chromaff in cells.
  • HY-114597
    PKF050-638

    HIV CRM1 Cancer
    PKF050-638 is a potent and selective inhibitor of HIV-1 Rev (IC50=0.04 μM). PKF050-638 inhibits the CRM1-mediated Rev nuclear export by disrupting CRM1-NES interaction.
  • HY-107573
    KDM2/7-IN-1

    Histone Demethylase Cancer
    KDM2/7-IN-1 (TC-E 5002) is a selective histone demethylase KDM2/7 subfamily inhibitor (IC50 values are 0.2, 1.2, 6.8, 55, 83, >100 and >120 μM for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A and KDM4A respectively). KDM2/7-IN-1 inhibits growth of HeLa and KYSE-150 cancer cells in vitro.
  • HY-N10538
    Shishijimicin B

    Others Cancer
    Shishijimicin B is an active compound of the enediyne class. Shishijimicin B shows extremely potent cytotoxicity with IC50 values of 2.0-3.3 nM. Shishijimicin B has antitumor activity and can be used for the research of cancer.
  • HY-16918A
    Heptamidine dimethanesulfonate

    SBi4211 dimethanesulfonate

    Others Cancer Inflammation/Immunology
    Heptamidine dimethanesulfonate (SBi4211 dimethanesulfonate) is a potent Pentamidine-related inhibitor of the calcium-binding protein S100B (Kd=6.9 μM), selectively kills melanoma cells with S100B over those without S100B. Heptamidine is a useful tool for the investigation of Myotonic dystrophy (DM).
  • HY-W054146
    RAMB4

    Proteasome Cancer
    RAMB4 is a ubiquitin-proteasome system (UPS)-stressor. RAMB4 inhibits ubiquitin-mediated protein degradation upstream of the 20S proteasomal catalytic activites. RAMB4 triggers a ubiquitin-proteasome-system (UPS)-stress response without affecting 20S proteasome catalytic activities. Anticancer activity.
  • HY-107485
    HIV-1 integrase inhibitor 8

    HIV Integrase Infection
    HIV-1 integrase inhibitor 8 is a HIV-1 integrase inhibitor, compound 8.
  • HY-16918
    Heptamidine

    SBi4211

    Others Cancer Inflammation/Immunology
    Heptamidine (SBi4211) is a potent Pentamidine-related inhibitor of the calcium-binding protein S100B (Kd=6.9 μM), selectively kills melanoma cells with S100B over those without S100B. Heptamidine is a useful tool for the investigation of Myotonic dystrophy (DM).
  • HY-117318
    PDE12-IN-1

    Phosphodiesterase (PDE) Infection
    PDE12-IN-1 is a potent and selective PDE12 inhibitor with a pIC50 value for enzyme inhibition of 9.1. PDE12-IN-1 increases 2′,5′-linked adenylate polymers (2-5A) levels, and the pEC50 value is 7.7. PDE12-IN-1 shows antiviral activity.
  • HY-N10540
    Aplyronine A

    Autophagy Apoptosis Cancer
    Aplyronine A is a specific actin-depolymerizing agent. Aplyronine A has antitumor and apoptosis effect. Aplyronine A can be used for the research of cancer and muscle contraction, cell motility and cell division.
  • HY-144450
    PI3K-IN-29

    PI3K Akt Cancer
    PI3K-IN-29 is a potent PI3K inhibitor. PI3K-IN-29 displays good inhibition potencies against U87MG, HeLa and HL60 cells with IC50 values of 0.264, 2.04 and 1.14 µM, respectively. PI3K-IN-29 inhibits PI3K/Akt pathway by inhibiting phosphorylation of Akt that is catalyzed by PI3K.
  • HY-108708
    GeA-69

    PARP Cancer
    GeA-69 is a selective, allosteric inhibitor of poly-adenosine-diphosphate-ribose polymerase 14 (PARP14) targeting macrodomain 2 (MD2), with a Kd value of 2.1 µM. GeA-69 involves in DNA damage repair mechanisms and prevents recruitment of PARP14 MD2 to sites of laser-induced DNA damage.
  • HY-148122
    NW 1028

    p97 Cancer
    NW 1028 is a potent VCP/p97 inhibitor. NW 1028 targets the ND1L domain of p97 and inhibits the degradation of a p97-dependent reporter. NW 1028 has good binding affinity with Kd values of 100 and 285 nM for ND1L and full length p97, respectively. NW 1028 has the function of regulating the mitotic spindle of cells.
  • HY-12003
    SNS-314 mesylate

    Aurora Kinase Cancer
    SNS-314 mesylate is a potent and selective aurora kinase inhibitor with IC50s of 9, 31, and 6 nM for aurora A, B and C, respectively.
  • HY-147892
    HDAC-IN-42

    HDAC Apoptosis Cancer
    HDAC-IN-42 (compound 14f) is a potent and selective HDAC inhibitor with IC50 values of 0.19 and 4.98 µM for HDAC1 and HDAC6, respectively. HDAC-IN-42 shows anticancer and anti-proliferative activity. HDAC-IN-42 induces apoptosis and cell cycle arrest at G2/M phase.
  • HY-108344
    SNS-314

    Aurora Kinase Cancer
    SNS-314 is a potent and selective aurora kinase inhibitor with IC50s of 9, 31, and 6 nM for aurora A, B and C, respectively.
  • HY-111548
    Spastazoline

    Others Others
    Spastazoline is a selective spastin (a microtubule-severing AAA protein) inhibitor, with an IC50 of 99 nM for Human spastin. Spastazoline can be used for cell division- and intracellular vesicle transport-related research.
  • HY-147738
    SQM-NBD

    Others Others
    SQM-NBD is a potent and selectiveAIE fluorescent probe. SQM-NBD exhibits excellent sensitivity to Cys and Hcy with the LOD of 54 nM and 72 nM, respectively.SQM-NBD has good cell permeability and low cytotoxicity. SQM-NBD has the potential for Cys/Hcy identification under physiological and pathological conditions.
  • HY-W028690
    DNMDP

    Phosphodiesterase (PDE) Cancer
    DNMDP, a phosphodiesterase 3A (PDE3A) inhibitor, is a potent and selective cancer cell cytotoxic agent. DNMDP binding to PDE3A promotes an interaction between PDE3A and Schlafen 12 (SLFN12). DNMDP shows clear cell-selective cytotoxicity.
  • HY-103255
    CFM-4

    Apoptosis Cancer
    CFM-4 is a potent small molecular antagonist of CARP-1/APC-2 binding. CFM-4 prevents CARP-1 binding with APC-2, causes G2M cell cycle arrest, and induces apoptosis with an IC50 range of 10-15 μM. CFM-4 also suppresses growth of drug-resistant human breast cancer cells.
  • HY-143303
    Anticancer agent 32

    Apoptosis Cancer
    Anticancer agent 32 (compound 2g) is an anticancer agent. Anticancer agent 32 shows anticancer activities, affects cell cycle and induces cell apoptosis. Anticancer agent 32 can be used for the research of cancer.
  • HY-134990
    Hematoporphyrin monomethyl ether

    Apoptosis Cancer
    Hematoporphyrin monomethyl ether, second generation of porphyrin-related photosensitizer, is characterized by its single form, high yield of singlet oxygen, high selectivity, and low toxicity, which has been widely used in the diagnosis and treatment of various tumors, including lung cancer, bladder cancer, and nevus flammeus and brain glioma.
  • HY-N6036
    Ganoderic acid F

    Others Cancer
    Ganoderic acid F is a ganoderic acid. Ganoderic acid F exhibits antitumor and antimetastatic activities through inhibition of angiogenesis and alteration of proteins involving cell proliferation and/or cell death, carcinogenesis, oxidative stress, calcium signaling, and endoplasmic reticulum stress.
  • HY-144132
    αβ-Tubulin-IN-1

    Apoptosis Microtubule/Tubulin Cancer
    αβ-Tubulin-IN-1 is a potent and orally active αβ-Tubulin inhibitor. αβ-Tubulin-IN-1 induces cell cycle arrest at G2/M and efficient apoptosis. αβ-Tubulin-IN-1 inhibits tumor cell migration and Metastasis. αβ-Tubulin-IN-1 shows significant antitumor efficacy in a dose dependent manner.
  • HY-16399
    Pladienolide B

    Apoptosis Cancer
    Pladienolide B is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the spliceosome. Pladienolide B exerts antitumor activities mediated through the inhibition of pre-mRNA splicing. Pladienolide B induces apoptosis.
  • HY-144334
    CHIKV-IN-3

    DNA/RNA Synthesis Infection
    CHIKV-IN-3 is a potent against two low-passage CHIKV inhibitor with EC50 values of 1.55 and 0.14 µM for CHIKV-122508 and CHIKV-6708, respectively. CHIKV-IN-3 acts on the host cells to interfere with the viral replication. CHIKV-IN-3 displays minimal cytotoxic liability(CC50 > 100 µM). Prophylactic effect.
  • HY-136348
    ML338

    Bacterial Infection
    ML338 is a selective small molecule inhibitor probe of non-replicating Mycobacterium tuberculosis bacilli and is against the non-replicating M. tuberculosis with IC90 and IC99 values of 1 μM and 4 μM, respectively by CFU. ML338 is a invaluable tool for identifying both essential functions and vulnerabilities of the M. tuberculosis bacilli in the nutrient deprivation states. ML338 can be used for the study of M. tuberculosis chemotherapy.
  • HY-14454
    TPh A

    Triphenyl Compound A

    Others Cancer
    TPh A (Triphenyl Compound A) is a potent inhibitor of the nuclear protein pirin and binds specifically to pirin with a Ki of 0.6 uM. TPh A disrupts the formation of the bcl3–pirin complex. TPh A can be used as a novel small molecule tool to regulate pirin in cells.
  • HY-146276
    CDK/HDAC-IN-2

    HDAC CDK Apoptosis Cancer
    CDK/HDAC-IN-2 is a potent HDAC/CDK dual inhibitor with IC50 of 6.4, 0.25, 45, >1000, 8.63, 0.30, >1000 nM for HDAC1, HDAC2, HDAC3, HDAC6,8, CDK1, CDK2, CDK4,6,7, respectively. CDK/HDAC-IN-2 shows excellent antiproliferative activities. CDK/HDAC-IN-2 induces apoptosis and cell cycle arrest at G2/M phase. CDK/HDAC-IN-2 shows potent antitumor efficacy.
  • HY-Y1750A
    β-Aminopropionitrile hydrochloride

    BAPN hydrochloride

    Monoamine Oxidase Endogenous Metabolite Cancer Metabolic Disease
    β-Aminopropionitrile (BAPN) hydrochloride is a specific, irreversible and orally active lysyl oxidase (LOX) inhibitor. β-Aminopropionitrile hydrochloride targets the active site of LOX or LOXL isoenzymes.
  • HY-N0316
    Mollugin

    NF-κB Reactive Oxygen Species Apoptosis VEGFR c-Myc Cancer
    Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway.
  • HY-Y1750
    β-Aminopropionitrile

    BAPN

    Monoamine Oxidase Endogenous Metabolite Cancer Metabolic Disease
    β-Aminopropionitrile (BAPN) is a specific, irreversible and orally active lysyl oxidase (LOX) inhibitor. β-Aminopropionitrile targets the active site of LOX or LOXL isoenzymes.
  • HY-149004
    SLF1081851

    LPL Receptor Inflammation/Immunology
    SLF1081851 is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 plays a key role in development and immune system.
  • HY-134050
    Apostatin-1

    Apt-1

    RIP kinase Autophagy Apoptosis Beclin1 Necroptosis Inflammation/Immunology
    Apostatin-1 (Apt-1) is a potent TRADD inhibitor. Apostatin-1 can bind with TRADD-N (KD=2.17 μM), disrupting its binding to both TRADD-C and TRAF2. Apostatin-1 modulates the ubiquitination of RIPK1 and beclin 1. Apostatin-1 blocks apoptosis and restores cellular homeostasis by activating autophagy in cells with accumulated mutant tau, α-synuclein, or huntingtin.
  • HY-P99171
    Gevokizumab

    Interleukin Related Inflammation/Immunology
    Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II).
  • HY-143302
    Anticancer agent 31

    Others Cancer
    Anticancer agent 31 is a 1,3-diphenylurea quinoxaline derivative, and a anticancer agent. Anticancer agent 31 exhibits antitumor acitvity by arresting cell cycle at S phase and inducing apoptosis.
  • HY-18174C
    Prexasertib mesylate

    LY2606368 mesylate

    Checkpoint Kinase (Chk) DNA/RNA Synthesis Apoptosis Cancer
    Prexasertib mesylate (LY2606368 mesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib mesylate inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib mesylate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib mesylate shows potent anti-tumor activity.